A simple eye-tracking test may replace button-pressing exams for pituitary tumor patients

NCT ID NCT06266949

First seen Jul 23, 2026 · Last updated Jul 24, 2026 · Updated 1 time

Summary

This study tests whether a new eye-tracking device called SONDA can accurately measure visual field loss in people with pituitary tumors. Standard visual field tests require patients to press a button when they see lights, which can be tiring and unreliable. The SONDA test instead tracks eye movements to map vision. Researchers will compare SONDA results with standard tests and check how consistent the measurements are across repeat sessions.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
SONDA eye-tracking visual field test
What this could lead to
If it works, this could offer a faster, easier way to detect vision loss from pituitary tumors without the need for a button-pressing response.
What could go wrong
This is a small, early-stage diagnostic study with only 30 participants. The test may not be accurate enough to replace current methods, and results may not apply to other types of vision loss.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PITUITARY TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Hemianopsia Pituitary Neoplasms pituitary tumor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • UMCG

    Groningen, Provincie Groningen, 9713 GZ, Netherlands

More trials for these conditions

Other studies related to the condition(s) this trial covers.